Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of STEMVAC Vaccine Therapy for Patients With Hormone Receptor Positive Metastatic Breast Cancer

NCT07112053 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT07112053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07112053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of STEMVAC Vaccine Therapy for Patients With Hormone Receptor Positive Metastatic Breast Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
November 17, 2025
Completion date
December 31, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, metastatic her2-negative breast carcinoma, metastatic hormone receptor-positive breast carcinoma